Efficacy of aprocitentan in patients across the cardiometabolic disease spectrum including obesity to be presented at AH

Idorsia Ltd (SIX: IDIA) announces positive findings from two new analyses of the pivotal Phase 3 PRECISION study highlighting the importance of endothelin pathway blockade in patients with obesity- associated resistant hypertension and across the cardiovascular-kidney-metabolic continuum. The findings will be presented in oral sessions at the American Heart Association Hypertension Scientific Sessions 2026, taking place in Arlington, Virginia, from October 7 to 11, 2026.

Targeting the upregulated endothelin pathway in patients with obesity and hypertension

Obesity and hypertension are closely interconnected. Hypertension is one of the most common comorbidities of obesity and is a major contributor to cardiovascular and kidney damage in this population. As the prevalence of obesity continues to rise, the number of people living with obesity-associated hypertension is also expected to increase.1

The obese population is more likely to develop hypertension that remains uncontrolled despite treatment with multiple antihypertensive medicines. The upregulation of the endothelin pathway appears to be an important system that had not been targeted in hypertension before aprocitentan. Adipose tissue releases endothelin-1, with greater release observed in obese people.1 Obesity is therefore associated with increased detrimental effects of endothelin-1.1-2 A new analysis of PRECISION evaluated aprocitentan in patients with resistant hypertension and obesity or severe obesity, many of whom were also living with diabetes, chronic kidney disease or albuminuria. The positive findings strengthen the evidence supporting endothelin pathway blockade in this population and provide new insights into the role of endothelin in obesity-associated resistant hypertension.

The results will be presented for the first time in an oral presentation by Dr. Michael A. Weber, MD: Endothelin is a driver of hypertension in individuals with obesity: A post hoc analysis of the PRECISION study. Markus Schlaich, Martine Clozel, Ruth Collins, Parisa Danaietash, John M. Flack, Johann Laurent, Krzysztof Narkiewicz, Ji-Guang Wang, and Michael A. Weber. Saturday, October 10, 5:15 PM | Abstract Session 19 | Number 83

Targeting the upregulated endothelin pathway in patients with CKM and hypertension

Cardiovascular-kidney-metabolic (CKM) syndrome is defined as a health disorder attributable to the interconnections among obesity, diabetes, chronic kidney disease, and cardiovascular disease.3,4 The risk of cardiovascular death nearly triples as CKM progresses from stages 0-1 to stage 4, while more than 64% of the US adult population is classified as CKM stages 2 to 4.3 Hypertension is a central driver across this continuum, contributing to chronic kidney disease progression, while dysfunction in the cardiovascular, kidney, and metabolic systems creates a self- reinforcing cycle that increases the risk of cardiovascular events, kidney failure, hospitalization and premature death.3-5 Endothelin has detrimental consequences relevant to multiple components of CKM syndrome, including blood pressure regulation, kidney function and metabolic effects such as aldosterone production. This provides a strong rationale for examining endothelin inhibition across different stages of CKM syndrome.

A new analysis of PRECISION evaluated aprocitentan across early and advanced CKM stages. The positive findings further characterize the effects of endothelin pathway blockade across the CKM continuum and provide new insights into blood pressure control and other measures relevant to cardiovascular, kidney and metabolic health.

The findings will be presented for the first time in an oral session at the congress by Dr. John M. Flack, MD: Endothelin as a therapeutic target across the cardiovascular-kidney-metabolic continuum: A post hoc analysis of the PRECISION study Markus Schlaich, Martine Clozel, Parisa Danaietash, Johann Laurent, Alessandro Maresta, Krzysztof Narkiewicz, Ji-Guang Wang, Michael A. Weber, and John M. Flack. Saturday, October 10, 2:30 PM | Abstract session 17 | Number 72

Join Idorsia at leading cardiovascular and kidney congresses

Idorsia will also be present at major US congresses, where it will host exhibitor spotlight sessions on “The Next Era in the Treatment of Hypertension.”

AHA Hypertension, Crystal City, VA, October 8-10. Visit us at Tables 25 and 26. Exhibitor Spotlight at Ballroom A & B on Friday, October 9, from 1:00 to 1:30 p.m.

ASN Kidney Week, Denver, CO, October 22-24. Visit us at Booth #1023. Exhibitor Spotlight at Theater #3 on Saturday, October 24, from 11:00 to 11:45 a.m.

AHA Scientific Sessions, Chicago, IL, November 7-9. Visit us at Booth #3014. Exhibitor Spotlight at Learning Studio #3 on Sunday, November 8, from 9:30 to 10:15 a.m.

For further information, please contact:

Investor & Media Relations
Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com